Phase 1 N=59 A Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetic Profile of a Single Doses of MMV533.
Malaria
Primary: The Tolerability and Safety of Ascending Single Oral Doses of MMV533 — 5; 3; 7; 4 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=20 Phase 1 Study To Evaluate Antiviral Activity Of Small Molecule Direct Antiviral Agent At Multiple Doses In Subjects With Chronically Infected Hepatitis C Virus.
Hepatitis, Chronic · Hepatitis C Virus
Primary: Change From Baseline in Plasma Log10 Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) at Day 11 (Cohort A): Full Analysis Set — 6.11; -0.45 log10 IU/mL
Phase 1 N=40 A Phase 1a Study of PMN310 In Healthy Volunteers
Healthy Participants
Primary: Incidence of Treatment Emergent Adverse Events — 2; 2; 0; 3 participants
Phase 1 N=62 Phase 1 Study of ELX-02 in Healthy Adult Subjects
Genetic Disease · Nonsense Mutation
Primary: Pharmacokinetic Parameters - Plasma AUC0-24 — 1105.126; 3125.484; 11018.22; 28235.823 ng*h/mL
Phase 1 N=40 Phase 1 Study of PBTZ169
Tuberculosis
Primary: Incidence of Drug-related Adverse Events [Safety and Tolerability] — 2; 2; 1; 0 participants
Phase 1 N=30 Phase 1 Novel Live Attenuated Serotype 2 Oral Polio Vaccine Study in Inactivated Polio Vaccine (IPV) Primed Adults
Poliomyelitis
Primary: Number of Participants With Serious Adverse Events and Severe Adverse Events Throughout the Study — 0; 0; 6; 9 Participants
Phase 1 N=36 Asian Phase I Study Of PF-03446962
Neoplasms
Primary: Maximum Tolerated Dose (MTD) — 10.0 mg/kg
Phase 1 N=66 Phase 1A Safety Trial of Inhaled PK10571 (GB002)
Safety Issues
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) — 0; 0; 2; 1 Participants
Phase 1 N=66 Phase 1 Study for IPG11406 in Health Volunteer
Inflammatory Bowel Diseases
Primary: Safety Indicators：Adverse Event — 1; 3; 2; 3 Participants
Phase 2 N=305 Phase 2a, Dose-ranging Study With PF-05221304 in Nonalcoholic Fatty Liver Disease (NAFLD)
Nonalcoholic Fatty Liver Disease · Nonalcoholic Steatohepatitis
Primary: Percent Change From Baseline in Liver Fat by Magnetic Resonance Imaging-Proton Density Fat Fraction (MRI- PDFF) at Week 16 — -7.2; -17.1; -49.9; -55.9 Percent change
Phase 1 N=56 First in Human Study of a Monoclonal Antibody (SOL-116) Targeting BSSL (Bile Salt-Stimulated Lipase), Single and Multiple Dose Parts
Rheumatoid Arthritis
Primary: Safety and Tolerability: Adverse Events — 7; 9; 8; 8 number of events
Phase 2 N=18 Phase 2, Randomized, Open-Label, Crossover, PD/PK Study of a Novel Pram-Insulin Co-Formulation in Adults With T1D
Diabetes Mellitus, Type 1 · Insulin-dependent Diabetes Mellitus
Primary: Area Under the Curve 0-180 Minutes for Plasma Glucose >180 mg/dL — 5019.6; 4591.9; 13317.5 min*mg/dL — p=<0.0001
Phase 1 N=76 Phase 1 Study of IPG1094 Safety, Tolerability, and PK in Healthy Participants
Healthy Volunteers
Primary: Adverse Events — 0; 2; 3; 3 Participants
Phase 1 N=48 Phase 1 Clinical Trial of Single-Vial ID93 + GLA-SE in Healthy Adults
Pulmonary TB
Primary: Local Injection Site Reactogenicity — 22; 21 participants
Phase 1 N=47 A Phase 1 Research Study to Evaluate Safety, Tolerability, and Pharmacokinetics of WVE-006 in Healthy Participants With Wild-type AAT Expression (RestorAATion-1)
Alpha-1 Antitrypsin Deficiency (AATD)
Primary: The Proportion of Participants With Adverse Events — 8; 5; 4; 3 Participants
Phase 1 N=42 Phase 1 Study of SAR440894 vs Placebo
Chikungunya Virus Infection
Primary: Frequency of Adverse Events (AEs) — 5; 3; 2; 3 Participants
N/A N=68 ACT1ON Phase 2 (SMART Pilot) and Phase 3 (Efficacy Trial Development)
Diabetes Mellitus, Type 1 · Overweight and Obesity
Primary: Change in Weight - Randomization 1 — -1.6; -1.8; -1.5 kilograms — p=0.98
Phase 1 N=12 Phase 1 Trial of PAN-301-1 (SNS-301) in Cancer Patients
Prostate Cancer
Primary: Safety Assessed by Development of Adverse Events and Dose-limiting Toxicity to Determine Maximum Tolerated Dose — 3; 3; 6; 0 Participants
Phase 1 N=39 Phase 1, TAK-648, Single-Rising Dose Study
Healthy Volunteers
Primary: Percentage of Participants Who Have at Least One Treatment-Emergent Adverse Event (TEAE) — 0; 50.0; 16.7; 0 percentage of participants
Phase 2 N=345 Phase 1/2 Study of Enasidenib (AG-221) in Adults With Advanced Hematologic Malignancies With an Isocitrate Dehydrogenase Isoform 2 (IDH2) Mutation
Hematologic Neoplasms
Primary: Phase 1 Dose Escalation: Number of Participants With Dose Limiting Toxicities (DLT) — 0; 0; 0; 0 Participants
Phase 1 N=24 A Phase 1 Study of EXT608 in Healthy Adults
Safety Issues
Primary: Characterize the Safety and Tolerability of EXT608 — 2; 2; 0; 0 Participants
Phase 2 N=32 Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of EP262 in Subjects With Atopic Dermatitis
Atopic Dermatitis
Primary: Number of Participants With Any Treatment-emergent Adverse Event (TEAE) — 4; 7 Participants
Phase 1 N=74 Phase 1 Evaluation of (2R,6R)-Hydroxynorketamine
Major Depressive Disorder
Primary: Number of Subjects With Adverse Events as a Measure of Safety and Tolerability of (2R,6R)-Hydroxynorketamine — 1; 0; 1; 1 Participants
Phase 2 N=22 A Phase 1/ Phase 2 Study of TTHX1114(NM141)
Corneal Endothelial Dystrophy · Fuchs Endothelial Corneal Dystrophy · Pseudophakic Bullous Keratopathy
Primary: DLTs/ Adverse Reactions — 0; 0; 0; 0 Participants
Phase 1 N=56 Phase 1 Single-ascending Dose Study to Evaluate Safety and Tolerability of MEDI4920 in Healthy Adults
Healthy Volunteer
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs) — 10; 1; 1; 5 Participants
Phase 1 N=135 Phase 1 Trial of a Malaria Vaccine in Young Kenyan Children
Plasmodium Falciparum Malaria
Primary: Occurrence of Solicited Symptoms During a 8 Day Follow-up Period After Each Vaccination — 24; 11; 35; 15 events
Phase 1 N=4 Absorption, Metabolism, Excretion and Pharmacokinetics of a Single Dose [14C]AZD2014 Followed by a Multiple Dose Phase
Solid Malignancies
Primary: Total Radioactivity in Plasma Following Administration of [14C]-AZD2014 — 4013; 3415; 2901; 2693 nanogram equivalent/millilitre (ngEq/mL)
Phase 1 N=56 Dose-finding Pharmacokinetic Study in Healthy Males
Healthy Volunteers
Primary: Levodopa Area Under the Concentration-time Curve From Time 0 to the 24 h PK Sample (AUC0-24) Time 0 to the 24 h PK Sample (AUC0-24) — 4300; 5423; 7439; 9046 h*ng/ml
Phase 1 N=114 Phase 1 TAK-041 First-in-Human Safety, Tolerability, and Pharmacokinetics Study
Healthy Volunteers · Schizophrenia
Primary: Percentage of Participants Who Experienced at Least One Treatment-Emergent Adverse Event (TEAE) — 40.0; 0; 0; 0 percentage of participants
Phase 1 N=18 Phase 1 Study to Determine the Effects of Food on the Pharmacokinetic Profile of PBT2
Healthy Volunteers
Primary: Area Under the Concentration-Time Curve (AUC 0-t) — 1490.0; 1273.0 h*ng/mL